# A mGlu2/3 Agonist in the Treatment of PTSD

> **NCT02234687** · PHASE1 · TERMINATED · sponsor: **NYU Langone Health** · enrollment: 10 (actual)

## Conditions studied

- Post-traumatic Stress Disorder

## Interventions

- **DRUG:** Pomaglumetad Methionil 160mg
- **DRUG:** Pomaglumetad Methionil 40mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02234687
- **Lead sponsor:** NYU Langone Health
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-09
- **Primary completion:** 2016-02-11
- **Final completion:** 2016-09-11
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** The original PI, Alexander Neumeister, left NYULMC. No data was analyzed.
- **Last updated:** 2018-11-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02234687

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02234687, "A mGlu2/3 Agonist in the Treatment of PTSD". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT02234687. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*